Isothermal Nucleic Acid Amplification Technology Market by Product (Assay, System), Technology (LAMP, SDA, NASBA, NEAR, HDA), Application (Diagnostics (Influenza, Hepatitis, CT/NG, COVID-19), blood screening), End User & Region - Global Forecast to 2028
Report Code: BT 2491 Mar, 2023, by marketsandmarkets.com
The global isothermal nucleic acid amplification technology market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to reach $6.8 billion by 2028, growing at a CAGR of 9.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the market is attributed to the cost-benefits of INAAT, rising prevalence of infectious diseases, and increasing number of blood transfusions and donations.
Attractive Opportunities in the Isothermal Nucleic Acid Amplification Technology Market
To know about the assumptions considered for the study, Request for Free Sample Report
Isothermal Nucleic Acid Amplification Technology Market Dynamics
Driver: Recent launches of INAAT consumables by prominent market players
Prominent market players have launched new kits, reagents, and systems based on INAAT in the last three years. Market players are now focusing on the increasing their R&D efforts in development of new product. For instance, in June 2022, Grifols (Spain) obtained the CE Mark for the Procleix Plasmodium Assay, a nucleic acid test (NAT) specifically validated for screening blood donors for malaria. In May 2022, Hologic, Inc. (US) received US Food and Drug Administration (FDA) approval for the Aptima CMV Quant Assay. This assay will quantify the viral load of cytomegalovirus (CMV) in patients who have had an organ or stem cell transplant.
Restraint: Unfavorable reimbursement scenario for in vitro diagnostic tests
The Centers for Medicare & Medicaid Services (CMS) reduced the Medicare reimbursement rate for COVID-19 tests based on high-throughput technology to USD 75 unless labs can process results in under two days. Medicare does not currently provide genetic testing coverage for individuals without a history of cancer. Similarly, according to MedPAC (Medicare Payment Advisory Commission), medical testing has seen a 40% decline in reimbursement over the last 40 years. This decline and additional budgetary concerns among healthcare systems will be a major obstacle to implementing novel diagnostic techniques in clinical laboratories.
Opportunity: INAAT tests as point-of-care tools
LAMP is the most used INAAT method for the development of POC tools. LAMP technology offers major advantages, such as high specificity provided by the primer design, use of a single enzyme, relatively low reaction time (<1 h), and high efficiency. The Detect COVID-19 Test (Detect Inc.) is a molecular in vitro diagnostic test for the qualitative detection of nucleic acid from the novel coronavirus SARS-CoV-2 that causes COVID-19.
Assay, kits and reagents segment accounted for the largest share of the isothermal nucleic acid amplification technology industry
Based on the product, the isothermal nucleic acid amplification technology market is segmented into assay, kits, and reagents, and systems. The assay, kits, and reagents segment accounted for the largest share in 2022. The largest share of this segment is attributed to increasing approvals of CLIA-waived tests, repeated purchase of reagents, and continuous launch of newer, faster, and more reliable POC products.
North America was the largest regional market for isothermal nucleic acid amplification technology industry in 2022.
The isothermal nucleic acid amplification technology market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market. Increasing number of research project on infectious disease diagnosis, rising demand for new INAAT systems and kits, and growing use of INAAT consumables are various factors projected to drive the growth of the market.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the market include Grifols, S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), Eiken Chemical Co., Ltd. (Japan), bioMérieux SA (France), Tecan Trading AG (Switzerland), New England Biolabs (US), QIAGEN N.V. (Germany), DiaSorin S.p.A. (Italy), General Electric (US), OptiGene Limited (UK), Quidel Corporation (US), Thermo Fisher Scientific (US), Genomtec (Poland), Mast Group Ltd. (UK), Ustar Biotechnologies (China), Jena Bioscience GmbH (Germany), Atila BioSystems (US), TwistDx Limited (UK), LGC Limited (UK), Life Sciences Advanced Technologies (US), GenoSensor Corporation (US), and PCR Biosystems (UK).
Scope of the Isothermal Nucleic Acid Amplification Technology Industry
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$4.4 billion |
|
Projected Revenue in 2028 |
$6.8 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 9.2% |
|
Market Driver |
Recent launches of INAAT consumables by prominent market players |
|
Market Opportunity |
INAAT tests as point-of-care tools |
The study categorizes the isothermal nucleic acid amplification technology market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Assays, Kits, & Reagents
- Systems
By Technology
- Transcription Mediated Amplification (TMA)
- Loop-mediated Isothermal Amplification (LAMP)
- Strand Displacement Amplification (SDA)
- Helicase-dependent Amplification (HDA)
- Nucleic Acid Sequence-based Amplification (NASBA)
- Nicking Enzyme Amplification Reaction (NEAR)
- Single Primer Isothermal Amplification (SPIA)
- Other Technologies
By Application
-
Disease Diagnosis
- Hepatitis
- Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
- Influenza
- Covid-19
- Other Disease Diagnosis
- Blood Screening
- Other Applications
By End User
- Hospitals
- Reference Laboratories
- Academic & Research Institutes
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- Indias
- Rest of Asia Pacific
- Latin America
- Middle East and Africa
Recent Developments of Isothermal Nucleic Acid Amplification Technology Industry
- In May 2022, Hologic, Inc. (US) received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system.
- In December 2021, Hologic, Inc. (US) launched Panther Trax, which offers full automation to meet high-volume testing demands and will be commercially available in the US, Europe, Canada, Australia, and New Zealand.
- In September 2020, Abbott (US) received approval from Health Canada for the ID NOW rapid COVID-19 testing device for use in Canada.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global isothermal nucleic acid amplification technology market?
The global isothermal nucleic acid amplification technology market boasts a total revenue value of $6.8 billion by 2028.
What is the estimated growth rate (CAGR) of the global isothermal nucleic acid amplification technology market?
The global isothermal nucleic acid amplification technology market has an estimated compound annual growth rate (CAGR) of 9.2% and a revenue size in the region of $4.4 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 34)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 39)
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 PRIMARY RESEARCH
FIGURE 3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET: PRIMARY RESPONDENTS
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY RESOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 7 MARKET: CAGR PROJECTIONS, 2023–2028
FIGURE 8 MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.4 DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT
3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 10 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 52)
4.1 MARKET OVERVIEW
FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 16 ASSAYS, KITS, AND REAGENTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 MARKET SHARE, BY APPLICATION, 2023 VS. 2028
FIGURE 17 DISEASE DIAGNOSIS APPLICATION SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 55)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Recent launches of INAAT consumables by prominent market players
5.2.1.2 Growing funding initiatives for molecular diagnostics & infectious disease diagnostics
5.2.1.3 High prevalence of infectious diseases
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for in vitro diagnostic tests
5.2.3 OPPORTUNITIES
5.2.3.1 INAAT tests as point-of-care tools
5.2.3.2 Start-ups focusing on INAAT
5.2.4 CHALLENGES
5.2.4.1 Dominance of PCR
5.3 PRICING ANALYSIS
TABLE 2 AVERAGE SELLING PRICE OF INAAT PRODUCTS, 2022
5.4 VALUE CHAIN ANALYSIS
FIGURE 20 VALUE CHAIN OF INAAT MARKET: MAXIMUM VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.5 ECOSYSTEM ANALYSIS
FIGURE 21 MARKET: ECOSYSTEM ANALYSIS
TABLE 3 SUPPLY CHAIN ECOSYSTEM
5.6 KEY CONFERENCES & EVENTS IN 2023–2024
TABLE 4 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT FROM NEW ENTRANTS
5.7.2 THREAT FROM SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 DEGREE OF COMPETITION
5.8 KEY STAKEHOLDERS & BUYING CRITERIA
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INAAT PRODUCTS
FIGURE 23 BUYING CRITERIA FOR INAAT PRODUCTS
5.9 PATENT ANALYSIS
FIGURE 24 PATENT APPLICATIONS RELATED TO MARKET, JANUARY 2012–DECEMBER 2022
5.10 REGULATORY ANALYSIS
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 Canada
5.10.2 EUROPE
TABLE 10 EUROPE: CLASSIFICATION OF DEVICES
5.10.3 ASIA PACIFIC
5.10.3.1 China
5.10.3.2 Japan
5.10.3.3 India
5.10.4 LATIN AMERICA
5.10.4.1 Brazil
5.10.4.2 Mexico
5.10.5 MIDDLE EAST
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25 REVENUE SHIFT AND NEW REVENUE POCKETS
6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT (Page No. - 72)
6.1 INTRODUCTION
TABLE 11 MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 ASSAYS, KITS, AND REAGENTS
6.2.1 GROWING AWARENESS OF INAAT TO DRIVE DEMAND FOR ASSAYS, KITS, AND REAGENTS
TABLE 12 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 13 NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 14 EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 15 ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 SYSTEMS
6.3.1 GROWING POPULARITY OF INAAT SYSTEMS TO SUPPORT MARKET GROWTH
TABLE 16 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY TECHNOLOGY (Page No. - 78)
7.1 INTRODUCTION
TABLE 20 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
TABLE 21 MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP)
7.2.1 LAUNCH OF NEW LAMP DIAGNOSTIC KITS TO SUPPORT MARKET GROWTH
TABLE 22 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 NORTH AMERICA: LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 EUROPE: LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 ASIA PACIFIC: LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA)
7.3.1 GROWING EFFORTS TO DEVELOP TMA KITS TO BOOST GROWTH
TABLE 26 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 NORTH AMERICA: TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EUROPE: TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 NICKING ENZYME AMPLIFICATION REACTION (NEAR)
7.4.1 RAPID IDENTIFICATION OF SMALL DNA OR RNA FRAGMENTS TO BOOST ADOPTION OF NEAR
TABLE 30 NICKING ENZYME AMPLIFICATION REACTION (NEAR) MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 31 NORTH AMERICA: NICKING ENZYME AMPLIFICATION REACTION (NEAR) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 EUROPE: NICKING ENZYME AMPLIFICATION REACTION (NEAR) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 ASIA PACIFIC: NICKING ENZYME AMPLIFICATION REACTION (NEAR) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 STRAND DISPLACEMENT AMPLIFICATION (SDA)
7.5.1 GROWING USE OF SDA IN RNA AMPLIFICATION TO PROPEL MARKET GROWTH
TABLE 34 STRAND DISPLACEMENT AMPLIFICATION (SDA) MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 35 NORTH AMERICA: STRAND DISPLACEMENT AMPLIFICATION (SDA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 EUROPE: STRAND DISPLACEMENT AMPLIFICATION (SDA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 ASIA PACIFIC: STRAND DISPLACEMENT AMPLIFICATION (SDA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 HELICASE-DEPENDENT AMPLIFICATION (HDA)
7.6.1 USE OF THERMOS TABLE HELICASE ENZYMES INSTEAD OF HEAT TO BOOST DEMAND FOR HDA
TABLE 38 HELICASE-DEPENDENT AMPLIFICATION (HDA) MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: HELICASE-DEPENDENT AMPLIFICATION (HDA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 EUROPE: HELICASE-DEPENDENT AMPLIFICATION (HDA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 ASIA PACIFIC: HELICASE-DEPENDENT AMPLIFICATION (HDA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.7 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA)
7.7.1 ADVANTAGES OF NASBA OVER PCR TO BOOST ADOPTION IN CLINICAL SETTINGS
TABLE 42 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 EUROPE: NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.8 SINGLE-PRIMER ISOTHERMAL AMPLIFICATION (SPIA)
7.8.1 USE OF RNA/DNA-3′ PRIMER FOR FIRST-STRAND CDNA SYNTHESIS TO DRIVE MARKET
TABLE 46 SINGLE-PRIMER ISOTHERMAL AMPLIFICATION (SPIA) MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: SINGLE-PRIMER ISOTHERMAL AMPLIFICATION (SPIA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: SINGLE-PRIMER ISOTHERMAL AMPLIFICATION (SPIA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 ASIA PACIFIC: SINGLE-PRIMER ISOTHERMAL AMPLIFICATION (SPIA) MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.9 OTHER TECHNOLOGIES
TABLE 50 OTHER INAAT TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: OTHER INAAT TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: OTHER INAAT TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: OTHER INAAT TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY APPLICATION (Page No. - 97)
8.1 INTRODUCTION
TABLE 54 MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 DISEASE DIAGNOSIS
TABLE 55 MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 56 MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 ASIA PACIFIC: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8.2.1 COVID-19
8.2.1.1 Extensive use of INAAT kits for COVID-19 diagnosis to support market growth
TABLE 60 MARKET FOR COVID-19 TESTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: MARKET FOR COVID-19 TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 EUROPE: MARKET FOR COVID-19 TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: MARKET FOR COVID-19 TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
8.2.2 HEPATITIS
8.2.2.1 Growing adoption of advanced technologies for diagnosis of hepatitis B to drive growth
FIGURE 26 NEW CASES OF HEPATITIS B AND HEPATITIS C WORLDWIDE, BY GENDER, 2020
TABLE 64 MARKET FOR HEPATITIS TESTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET FOR HEPATITIS TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 EUROPE: MARKET FOR HEPATITIS TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 ASIA PACIFIC: MARKET FOR HEPATITIS TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
8.2.3 CT/NG
8.2.3.1 Growing prevalence of CT/NG infections worldwide to boost market
TABLE 68 MARKET FOR CT/NG TESTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET FOR CT/NG TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 EUROPE: MARKET FOR CT/NG TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 ASIA PACIFIC: MARKET FOR CT/NG TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
8.2.4 INFLUENZA
8.2.4.1 Growing focus on containing spread of influenza to propel growth
TABLE 72 MARKET FOR INFLUENZA TESTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET FOR INFLUENZA TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR INFLUENZA TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 ASIA PACIFIC: TECHNOLOGY MARKET FOR INFLUENZA TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
8.2.5 HIV
8.2.5.1 High global incidence of HIV to support market growth
TABLE 76 GLOBAL HIV CASES, 2021
TABLE 77 MARKET FOR HIV TESTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 78 NORTH AMERICA: MARKET FOR HIV TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: MARKET FOR HIV TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 ASIA PACIFIC: MARKET FOR HIV TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
8.2.6 OTHER DISEASES
TABLE 81 MARKET FOR OTHER DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 82 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 EUROPE: MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 ASIA PACIFIC: MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 BLOOD SCREENING
8.3.1 INCREASING NUMBER OF BLOOD DONATIONS AND TRANSFUSIONS TO INCREASE USE OF INAAT IN BLOOD SCREENING APPLICATIONS
TABLE 85 MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET FOR BLOOD SCREENING APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 EUROPE: MARKET FOR BLOOD SCREENING APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 ASIA PACIFIC: MARKET FOR BLOOD SCREENING APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 OTHER APPLICATIONS
TABLE 89 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 92 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
9 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY END USER (Page No. - 116)
9.1 INTRODUCTION
TABLE 93 MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS
9.2.1 HOSPITALS TO DOMINATE INAAT MARKET DURING FORECAST PERIOD
TABLE 94 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 REFERENCE LABORATORIES
9.3.1 AVAILABILITY OF WIDE RANGE OF TEST PANELS FOR INFECTIOUS DISEASE TESTING TO SUPPORT MARKET
TABLE 98 MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 EUROPE: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 GROWING USE OF INAAT ASSAYS BY ACADEMIC & RESEARCH INSTITUTES TO BOOST MARKET
TABLE 102 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 103 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 OTHER END USERS
TABLE 106 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 107 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
10 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY REGION (Page No. - 125)
10.1 INTRODUCTION
TABLE 110 MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET SNAPSHOT
TABLE 111 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 113 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 US
10.2.1.1 Increasing approvals of INAAT products to drive market growth
TABLE 117 US: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 118 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 119 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 120 US: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 121 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Growing demand for molecular diagnostic kits to boost adoption of INAAT
TABLE 122 CANADA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 123 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 124 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 125 CANADA: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 127 EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 128 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 129 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 130 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 131 EUROPE: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany to dominate European isothermal nucleic acid amplification technology market during forecast period
TABLE 133 GERMANY: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 134 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 136 GERMANY: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 UK
10.3.2.1 Growing adoption of INAAT products to support market growth in UK
TABLE 138 NUMBER OF BLOOD DONATIONS IN UK, 2016–2020
TABLE 139 UK: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 140 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 141 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 142 UK: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Established blood screening regulations to boost growth
TABLE 144 HIV DATA FOR FRANCE, 2021
TABLE 145 FRANCE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 146 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 147 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 148 FRANCE: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Favorable government initiatives for blood transfusion to support growth
TABLE 150 HIV DATA FOR ITALY, 2021
TABLE 151 ITALY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 152 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 153 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 154 ITALY: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 155 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Growing demand for diagnostic testing in Spain to favor market growth
TABLE 156 HIV DATA FOR SPAIN, 2021
TABLE 157 SPAIN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 158 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 159 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 160 SPAIN: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 162 REST OF EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 163 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 164 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 165 REST OF EUROPE: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET SNAPSHOT
TABLE 167 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 168 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 169 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 170 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 171 ASIA PACIFIC: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 CHINA
10.4.1.1 China to dominate APAC INAAT market during forecast period
TABLE 173 CHINA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 174 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 175 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 176 CHINA: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 178 JAPAN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 179 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 180 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 181 JAPAN: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Government initiatives for blood donation to contribute to growth
TABLE 183 INDIA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 184 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 185 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 186 INDIA: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 188 REST OF ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 189 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 190 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 191 REST OF ASIA PACIFIC: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 LATIN AMERICA
10.5.1 GROWING AWARENESS ABOUT INAAT TO PROPEL GROWTH
TABLE 193 LATIN AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 194 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 195 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 196 LATIN AMERICA: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.2 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
TABLE 198 MIDDLE EAST & AFRICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 199 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 200 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 201 MIDDLE EAST & AFRICA: MARKET FOR DISEASE DIAGNOSIS APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE (Page No. - 177)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 29 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET: STRATEGIES ADOPTED
11.3 REVENUE SHARE ANALYSIS
FIGURE 30 REVENUE ANALYSIS OF KEY COMPANIES (2020–2022)
11.4 MARKET SHARE ANALYSIS
FIGURE 31 MARKET SHARE ANALYSIS OF KEY COMPANIES (2022)
TABLE 203 INAAT MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 32 MARKET: COMPANY EVALUATION MATRIX, 2022
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
11.6.1 OVERALL COMPANY FOOTPRINT (25 COMPANIES)
TABLE 204 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
11.6.2 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 205 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
11.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 206 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES
11.7.1 PROGRESSIVE COMPANIES
11.7.2 STARTING BLOCKS
11.7.3 RESPONSIVE COMPANIES
11.7.4 DYNAMIC COMPANIES
FIGURE 33 MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
11.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
TABLE 207 MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 208 MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
11.9 COMPETITIVE SCENARIO AND TRENDS
11.9.1 PRODUCT LAUNCHES
TABLE 209 MARKET: KEY PRODUCT LAUNCHES, JANUARY 2020– JANUARY 2023
11.9.2 DEALS
TABLE 210 MARKET: KEY DEALS, JANUARY 2020–JANUARY 2023
11.9.3 OTHER DEVELOPMENTS
TABLE 211 MARKET: OTHER KEY DEVELOPMENTS, JANUARY 2020–JANUARY 2023
12 COMPANY PROFILES (Page No. - 188)
12.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses & competitive threats)*
12.1.1 HOLOGIC, INC.
TABLE 212 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 34 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
12.1.2 ABBOTT LABORATORIES
TABLE 213 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
12.1.3 GRIFOLS, S.A.
TABLE 214 GRIFOLS, S.A.: BUSINESS OVERVIEW
FIGURE 36 GRIFOLS, S.A.: COMPANY SNAPSHOT (2021)
12.1.4 BECTON, DICKINSON AND COMPANY
TABLE 215 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
12.1.5 MERIDIAN BIOSCIENCE
TABLE 216 MERIDIAN BIOSCIENCE: BUSINESS OVERVIEW
FIGURE 38 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2022)
12.1.6 EIKEN CHEMICAL CO., LTD.
TABLE 217 EIKEN CHEMICAL CO., LTD.: BUSINESS OVERVIEW
FIGURE 39 EIKEN CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2021)
12.1.7 QUIDEL CORPORATION
TABLE 218 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 40 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
12.1.8 QIAGEN N.V.
TABLE 219 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 41 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.9 NEW ENGLAND BIOLABS
TABLE 220 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW
12.1.10 DIASORIN S.P.A.
TABLE 221 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 42 DIASORIN S.P.A.: COMPANY SNAPSHOT (2021)
12.1.11 BIOMÉRIEUX SA
TABLE 222 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 43 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
12.1.12 TECAN TRADING GROUP
TABLE 223 TECAN TRADING GROUP: BUSINESS OVERVIEW
FIGURE 44 TECAN TRADING GROUP: COMPANY SNAPSHOT (2021)
12.1.13 GENERAL ELECTRIC COMPANY
TABLE 224 GENERAL ELECTRIC COMPANY: BUSINESS OVERVIEW
FIGURE 45 GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT (2021)
12.1.14 THERMO FISHER SCIENTIFIC
TABLE 225 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 46 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
12.1.15 OPTIGENE LIMITED
TABLE 226 OPTIGENE LIMITED: BUSINESS OVERVIEW
12.2 OTHER COMPANIES
12.2.1 LGC LIMITED
12.2.2 USTAR BIOTECHNOLOGIES
12.2.3 TWISTDX LIMITED
12.2.4 MAST GROUP LTD.
12.2.5 GENOMTEC
12.2.6 GENOSENSOR CORPORATION
12.2.7 JENA BIOSCIENCE GMBH
12.2.8 LIFE SCIENCES ADVANCED TECHNOLOGIES
12.2.9 PCR BIOSYSTEMS
12.2.10 ATILA BIOSYSTEMS
*Details on Business overview, Products offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses & competitive threats might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 229)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the isothermal nucleic acid amplification technology market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the isothermal nucleic acid amplification technology market. The secondary sources used for this study include Press Releases, Annual Reports, White Papers, Certified Publications, Articles form authorized authors, Directories and Databases, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the isothermal nucleic acid amplification technology market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the INAAT products business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global isothermal nucleic acid amplification technology market based on the product, application, technology, end user, and region.
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities).
- To strategically analyse micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
- To strategically profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
- To track and analyse competitive developments such as product launches and approvals in the market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe market, by country
- Further breakdown of the Rest of Asia Pacific market, by country
- Further breakdown of the market in Latin America and the Middle East & Africa, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Generating Response ...
Growth opportunities and latent adjacency in Isothermal Nucleic Acid Amplification Technology Market